Mga Batayang Estadistika
| LEI | 549300X0O3003W5QYQ48 |
| CIK | 1435049 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Chinook Therapeutics Inc
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| November 22, 2023 |
KDNY / Chinook Therapeutics Inc / Samsara BioCapital, L.P. - SC 13D/A Activist Investment SC 13D/A 1 tm2331344d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Chinook Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 16961L 106 (CUSIP Number) Abrar Hussain Samsara BioCapital GP, LLC 628 Middlefield Road Palo Al |
|
| August 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37345 Chinook Therapeutics, Inc. (Exact name of registrant as specified |
|
| August 11, 2023 |
As filed with the Securities and Exchange Commission on August 11, 2023 As filed with the Securities and Exchange Commission on August 11, 2023 Registration No. |
|
| August 11, 2023 |
As filed with the Securities and Exchange Commission on August 11, 2023 POSASR As filed with the Securities and Exchange Commission on August 11, 2023 Registration No. |
|
| August 11, 2023 |
As filed with the Securities and Exchange Commission on August 11, 2023 As filed with the Securities and Exchange Commission on August 11, 2023 Registration No. |
|
| August 11, 2023 |
Certificate of Incorporation Cherry Merger Sub Inc. EX-3.1 Exhibit 3.1 Certificate of Incorporation of Cherry Merger Sub Inc. 1. The name of the corporation is “Cherry Merger Sub Inc.” (the “Corporation”). 2. The address of the Corporation’s registered office is Corporation Service Company, 251 Little Falls Drive, New Castle County Wilmington, Delaware 19808. The Corporation Service Company is the Corporation’s registered agent at that address. 3. |
|
| August 11, 2023 |
As filed with the Securities and Exchange Commission on August 11, 2023 S-8 POS As filed with the Securities and Exchange Commission on August 11, 2023 Registration No. |
|
| August 11, 2023 |
KDNY / Chinook Therapeutics Inc / Farallon Capital Partners, L.P. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 11, 2023 |
As filed with the Securities and Exchange Commission on August 11, 2023 As filed with the Securities and Exchange Commission on August 11, 2023 Registration No. |
|
| August 11, 2023 |
As filed with the Securities and Exchange Commission on August 11, 2023 As filed with the Securities and Exchange Commission on August 11, 2023 Registration No. |
|
| August 11, 2023 |
As filed with the Securities and Exchange Commission on August 11, 2023 S-8 POS As filed with the Securities and Exchange Commission on August 11, 2023 Registration No. |
|
| August 11, 2023 |
As filed with the Securities and Exchange Commission on August 11, 2023 S-8 POS As filed with the Securities and Exchange Commission on August 11, 2023 Registration No. |
|
| August 11, 2023 |
As filed with the Securities and Exchange Commission on August 11, 2023 As filed with the Securities and Exchange Commission on August 11, 2023 Registration No. |
|
| August 11, 2023 |
BYLAWS CHERRY MERGER SUB INC. ARTICLE I Exhibit 3.2 EXECUTION VERSION BYLAWS OF CHERRY MERGER SUB INC. ARTICLE I OFFICES SECTION 1. Registered Office. The registered office of Cherry Merger Sub Inc. (the “Corporation”) shall be established and maintained at the office of Corporation Service Company, in the City of Wilmington, in the County of New Castle, in the State of Delaware, and said company shall be the registered agent of the Cor |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 Chinook Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commiss |
|
| August 11, 2023 |
As filed with the Securities and Exchange Commission on August 11, 2023 As filed with the Securities and Exchange Commission on August 11, 2023 Registration No. |
|
| August 11, 2023 |
As filed with the Securities and Exchange Commission on August 11, 2023 As filed with the Securities and Exchange Commission on August 11, 2023 Registration No. |
|
| August 11, 2023 |
As filed with the Securities and Exchange Commission on August 11, 2023 POS AM As filed with the Securities and Exchange Commission on August 11, 2023 Registration No. |
|
| August 11, 2023 |
As filed with the Securities and Exchange Commission on August 11, 2023 As filed with the Securities and Exchange Commission on August 11, 2023 Registration No. |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37345 CHINOOK THE |
|
| August 7, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CHINOOK THERAPEUTICS, INC. Chinook Therapeutics, Inc. (hereinafter called the “Company”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify as follows: 1. That the name of this Company is Chinook Therapeuti |
|
| August 7, 2023 |
Amended and Restated 2015 Equity Incentive Plan Exhibit 10.1 Chinook Therapeutics, INC. Amended And Restated 2015 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 30, 2015 APPROVED BY THE STOCKHOLDERS: APRIL 1, 2015 IPO DATE/EFFECTIVE DATE: APRIL 15, 2015 As Amended and Restated on June 9, 2023 1. GENERAL. (a) Successor to and Continuation of Prior Plan. (i) The Plan is the successor to and continuation of the Aduro Biotech 2009 S |
|
| August 3, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 Chinook Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commissi |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| July 28, 2023 |
Exhibit 99.1 Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy SEATTLE July 28, 2023 – Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient wit |
|
| July 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2023 Chinook Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commissio |
|
| July 26, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| July 10, 2023 |
DEFM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant o Filed by a Party other than the Registrant 🗹 Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule14a-6 |
|
| June 27, 2023 |
PREM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 27, 2023 |
EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Chinook Therapeutics, Inc. |
|
| June 20, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2023 Chinook Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (C |
|
| June 20, 2023 |
Chinook Therapeutics Presents Data from EX-99.1 Exhibit 99.1 Chinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress June 17, 2023 • CHK-336 was generally well tolerated in healthy volunteers (HV) who received single doses up to 500 mg and multiple doses up to 60 mg for 14 days • Pha |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2023 Chinook Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commissio |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 Chinook Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commission |
|
| June 14, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2023 Chinook Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commissio |
|
| June 12, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2023 Chinook Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (C |
|
| June 12, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2023 Chinook Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (C |
|
| June 12, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt |
|
| June 12, 2023 |
EX-99.1 Exhibit 99.1 Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress • Zigakibart treatment continues to demonstrate rapid and sustained reductions in mechanistic biomarkers, including IgA and Gd-IgA1 levels, which correspond to clinically meaningful proteinuria re |
|
| June 12, 2023 |
Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AG EX-99.1 Exhibit 99.1 Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AG • Novartis to acquire Chinook for $40 per share in cash, with potential to receive up to an additional $4 per share in cash through contingent value rights, for a total equity value of up to approximately $3.5 billion • Chinook’s diversified pipeline of potentially best-in-class programs for rare, severe |
|
| June 12, 2023 |
EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER DATED AS OF JUNE 11, 2023, AMONG NOVARTIS AG, CHERRY MERGER SUB INC. AND CHINOOK THERAPEUTICS, INC. Table of Contents Page ARTICLE I DEFINITIONS 1 SECTION 1.01 Definitions 1 SECTION 1.02 Interpretation and Rules of Construction 10 ARTICLE II THE MERGER 11 SECTION 2.01 The Merger 11 SECTION 2.02 Merger Closing 11 SECTION 2.03 Effective Time 11 SECTION |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2023 Chinook Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commissio |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule14a-6( |
|
| May 9, 2023 |
Chinook Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Updates Exhibit 99.1 Chinook Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Updates SEATTLE May 9, 2023 – Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today reported financial results for the first quarter ended March 31, 2023 and provided corp |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 Chinook Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commission |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37345 CHINOOK TH |
|
| May 5, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission |
|
| April 28, 2023 |
Definitive Proxy Statement on Schedule 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only ( |
|
| April 28, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt |
|
| April 17, 2023 |
PRE 14A 1 d480268dpre14a.htm PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confident |
|
| April 13, 2023 |
Chinook Therapeutics Announces the Appointment of Robert W. Azelby to its Board of Directors EX-99.1 Exhibit 99.1 Chinook Therapeutics Announces the Appointment of Robert W. Azelby to its Board of Directors SEATTLE April 13, 2023 – Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Robert W. Azelby to its Board of Directors. Mr. Aze |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2023 Chinook Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commissi |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Chinook Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commissi |
|
| March 10, 2023 |
KDNY / Chinook Therapeutics Inc / Versant Venture Capital VII, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 6)* Chinook Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 16961L 106 (CUSIP Number) V |
|
| February 27, 2023 |
EX107 Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Chinook Therapeutics, Inc. |
|
| February 27, 2023 |
Power of Attorney (included on the signature page to this Registration Statement) S-8 As filed with the Securities and Exchange Commission on February 27, 2023 Registration No. |
|
| February 27, 2023 |
Exhibit 99.1 Chinook Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates SEATTLE February 27, 2023 – Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today reported financial results for the fourth quarter and year ended D |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 Chinook Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commi |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37345 CHINOOK THERAPE |
|
| February 27, 2023 |
Subsidiaries of the Registrant. Exhibit 21.1 The following table presents the name of significant subsidiaries of Chinook Therapeutics, Inc. and the location of jurisdiction or organization for such subsidiaries. Name: Jurisdiction/Organization Chinook Therapeutics U.S, Inc. Delaware Chinook Therapeutics Canada, Inc. British Columbia, CA Aduro Biotech Holdings, Europe B.V. Netherlands Aduro Biotech Europe B.V. Netherlands Aduro |
|
| February 24, 2023 |
Amended and Restated Bylaws of the Registrant. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF CHINOOK THERAPEUTICS, INC. (FORMERLY KNOWN AS ADURO BIOTECH, INC.) (A DELAWARE CORPORATION) As Amended and Restated on February 23, 2023 Table of Contents Page ARTICLE I OFFICES 1 Section 1.1 Registered Office 1 Section 1.2 Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 2.1 Corporate Seal 1 ARTICLE III STOCKHOLDERS’ MEETINGS 1 Section 3.1 Plac |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 Chinook Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commi |
|
| February 14, 2023 |
SC 13G/A 1 pt7213ga.htm SCHEDULE 13G/A, AMENDMENT #1 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Chinook Therapeutics, Inc. (Titl |
|
| February 14, 2023 |
KDNY / Chinook Therapeutics Inc / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-kdny123122a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Chinook Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 16961L106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) |
|
| February 14, 2023 |
SC 13G/A 1 d431875dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Chinook Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 16961L 106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| December 28, 2022 |
KDNY / Chinook Therapeutics Inc / Versant Venture Capital VII, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 5)* Chinook Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 16961L 106 (CUSIP Number) Versant Ve |
|
| November 10, 2022 |
Exhibit 10.2 AMENDMENT NO. 1 TO SALES AGREEMENT November 10, 2022 Chinook Therapeutics, Inc. 400 Fairview Avenue North, Suite 900 Seattle, WA 98109 Ladies and Gentlemen: Chinook Therapeutics, Inc., a Delaware corporation (the ?Company?), together with SVB Securities LLC (formerly SVB Leerink LLC) (?SVB Securities?) and Cantor Fitzgerald & Co. (?Cantor?; each individually an ?Agent? and together, t |
|
| November 10, 2022 |
2022 Equity Inducement Plan and forms of award agreements thereunder Exhibit 99.1 CHINOOK THERAPEUTICS, INC. 2022 EQUITY INDUCEMENT PLAN 1. GENERAL. (a) Purpose. The Plan, through the granting of Awards, is intended to help the Company secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate, and provide a means by which the eligible recipients may bene |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37345 CHINOO |
|
| November 10, 2022 |
CHINOOK THERAPEUTICS, INC. Up to $150,000,000 Common Stock Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-265168 PROSPECTUS SUPPLEMENT (To Prospectus dated May 24, 2022) CHINOOK THERAPEUTICS, INC. Up to $150,000,000 Common Stock We have previously entered into a Sales Agreement dated April 7, 2021, as amended by the Amended and Restated Amendment No. 1 to the Sales Agreement dated November 10, 2022, or the sales agreement, with SV |
|
| November 10, 2022 |
Chinook Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results Exhibit 99.1 Chinook Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results SEATTLE November 10, 2022 ? Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the quarter and nine |
|
| November 10, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLE 424(b)(5) (Form Type) Chinook Therapeutics, Inc. |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Chinook Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commi |
|
| November 10, 2022 |
As filed with the Securities and Exchange Commission on November 10, 2022 As filed with the Securities and Exchange Commission on November 10, 2022 Registration No. |
|
| November 10, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Chinook Therapeutics, Inc. |
|
| August 22, 2022 |
KDNY / Chinook Therapeutics Inc / Versant Venture Capital VII, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 4)* Chinook Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 16961L 106 (CUSIP Number) Versant Ve |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37345 CHINOOK THE |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 Chinook Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commissi |
|
| August 8, 2022 |
Chinook Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results Exhibit 99.1 Chinook Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results SEATTLE August 8, 2022 ? Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the quarter and six mon |
|
| June 7, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi |
|
| June 7, 2022 |
KDNY / Chinook Therapeutics Inc / Point72 Asset Management, L.P. - SCHEDULE 13G Passive Investment 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.)* (Name of Issuer) Chinook Therapeutics, Inc. (Title of Class of Securities) Common Stock, Par Value $0.00 |
|
| June 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2022 Chinook Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commission |
|
| June 1, 2022 |
KDNY / Chinook Therapeutics Inc / Samsara BioCapital, L.P. - SC 13D Activist Investment SC 13D 1 tm2217378d1sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Chinook Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 16961L 106 (CUSIP Number) Abrar Hussain Samsara BioCapital GP, LLC 628 Middlefield Road Palo Alto, CA |
|
| May 25, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 CHINOOK THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37345 94-3348934 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 25, 2022 |
Chinook Therapeutics Announces Pricing of a $105 Million Public Offering Exhibit 99.1 Chinook Therapeutics Announces Pricing of a $105 Million Public Offering SEATTLE, May 24, 2022 ? Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced the pricing of its underwritten public offering of 6,428,572 shares of its common stock at a price to the public of $14.00 per share. In addition, and in lieu of common stock, Chinook is offering to certain investors pre-funded warr |
|
| May 25, 2022 |
Exhibit 1.1 CHINOOK THERAPEUTICS, INC. (a Delaware corporation) 6,428,572 Shares of Common Stock and Pre-Funded Warrants to Purchase 1,071,428 Shares of Common Stock UNDERWRITING AGREEMENT May 24, 2022 SVB Securities LLC Cantor Fitzgerald & Co. William Blair & Company, L.L.C. as Representatives of the several Underwriters c/o SVB Securities LLC 255 California Street, 12th Floor San Francisco, Cali |
|
| May 25, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-265168 PROSPECTUS SUPPLEMENT (To Prospectus dated May 24, 2022) 6,428,572 Shares of Common Stock Pre-funded Warrants to Purchase 1,071,428 Shares of Common Stock CHINOOK THERAPEUTICS, INC. We are offering 6,428,572 shares of our common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants |
|
| May 25, 2022 |
2022 Form of Warrant to Purchase Common Stock Exhibit 4.1 CHINOOK THERAPEUTICS, INC. FORM OF WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. [ ] Original Issue Date: [ ], 2022 Chinook Therapeutics, Inc., a Delaware corporation (the ?Company?), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns (the ?H |
|
| May 25, 2022 |
EX-FILING FEES 2 d315490dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form 424(b)(5) (Form Type) Chinook Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule (1) Amount Registered Proposed Maximum Offering Price Per Uni |
|
| May 24, 2022 |
Exhibit 4.3 FORM OF DEBT SECURITY [Face of Security] CHINOOK THERAPEUTICS, INC. [If applicable, insert?FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS ?PRINCIPAL AMOUNT?), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT, THE YIELD TO |
|
| May 24, 2022 |
424B5 1 d315490d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-265168 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying pros |
|
| May 24, 2022 |
As filed with the Securities and Exchange Commission on May 24, 2022 Table of Contents As filed with the Securities and Exchange Commission on May 24, 2022 Registration No. |
|
| May 24, 2022 |
Exhibit 4.4 CHINOOK THERAPEUTICS, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1 ? DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION 4 ARTICLE 2 ? THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES 5 2.3. EX |
|
| May 24, 2022 |
EX-FILING FEES 6 d315490dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3ASR (Form Type) Chinook Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maxim |
|
| May 20, 2022 |
Exhibit 99.1 Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022 ? All patients with IgAN in Cohort 1 have transitioned to subcutaneous (SC) dosing, and BION-1301 remains well-tolerated, with no serious adverse events ( |
|
| May 20, 2022 |
Exhibit 99.2 Chinook Therapeutics Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at the 59th European Renal Association (ERA) Congress 2022 ? The AFFINITY IgAN cohort of 20 patients is fully enrolled, with 70% of patients in the study having baseline proteinuria over one gram per day despite maximal RAS inhibitor treatment, representin |
|
| May 20, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2022 Chinook Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commission |
|
| May 12, 2022 |
Chinook Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results Exhibit 99.1 Chinook Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results SEATTLE May 12, 2022 ? Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the first quarter ended Ma |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 Chinook Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commission |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37345 CHINOOK TH |
|
| April 29, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| April 29, 2022 |
EXHIBIT A AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Chinook Therapeutics, Inc. |
|
| April 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 14, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only ( |
|
| April 13, 2022 |
KDNY / Chinook Therapeutics Inc / Versant Venture Capital VII, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3)* Chinook Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 16961L 106 (CUSIP Number) Versant Ve |
|
| March 21, 2022 |
Chinook Therapeutics Announces Appointment of Dr. Mahesh Krishnan to its Board of Directors Exhibit 99.1 Chinook Therapeutics Announces Appointment of Dr. Mahesh Krishnan to its Board of Directors SEATTLE March 21, 2022 ? Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Mahesh Krishnan, M.D., M.P.H., M.B.A., FASN to its Board of |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2022 Chinook Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commissi |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37345 CHINOOK THERAPE |
|
| March 17, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2022 Chinook Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commissi |
|
| March 17, 2022 |
Exhibit 10.26 Execution Copy Confidential CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO CHINOOK THERAPEUTICS, INC. IF PUBLICLY DISCLOSED. LICENSE AGREEMENT This License Agreement (the ?Agreement?) is entered into on November 24, 2021 (the ?Execution Date?), by and between Chinook |
|
| March 17, 2022 |
Exhibit 10.25 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO CHINOOK THERAPEUTICS, INC. IF PUBLICLY DISCLOSED. SHAREHOLDERS AGREEMENT This SHAREHOLDERS AGREEMENT (this ?Agreement?) is entered into on December 8, 2021 (the ?Effective Date?), by and among: 1. SanReno Therapeutics Hol |
|
| March 17, 2022 |
Subsidiaries of the Registrant Exhibit 21.1 The following table presents the name of significant subsidiaries of Chinook Therapeutics, Inc. and the location of jurisdiction or organization for such subsidiaries. Name: Jurisdiction/Organization Chinook Therapeutics U.S, Inc. Delaware Chinook Therapeutics Canada, Inc. British Columbia, CA Aduro Biotech Holdings, Europe B.V. Netherlands Aduro Biotech Europe B.V. Netherlands Aduro |
|
| March 17, 2022 |
Power of Attorney (included on the signature page to this Registration Statement) As filed with the Securities and Exchange Commission on March 17, 2022 Registration No. |
|
| March 17, 2022 |
Separation Agreement between the Registrant and Alan Glicklich, dated January 26, 2022. EX-10.27 4 kdny-ex10271170.htm EX-10.27 Exhibit 10.27 January 28, 2022 Via Email Alan Glicklich Re:Terms of Separation Dear Alan: This letter confirms the agreement (“Agreement”) between you and Chinook Therapeutics, Inc. (the “Company”) concerning the terms of your resignation and offers you the separation compensation we discussed in exchange for a general release of claims and covenant not to s |
|
| March 17, 2022 |
EX-FILING FEES 4 d333263dexfilingfees.htm EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Chinook Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Ra |
|
| March 17, 2022 |
Exhibit 99.1 Chinook Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results SEATTLE March 17, 2022 ? Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the fourt |
|
| February 22, 2022 |
CUSIP No. 00739L101 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Chinook Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00739L101 (CUSIP Number) Morningside Venture (VI) Investments Ltd. C/O THC Management Services S.A.M. 2nd Floor, Le |
|
| February 16, 2022 |
KDNY / Chinook Therapeutics Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2022 Chinook Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commis |
|
| January 21, 2022 |
KDNY / Chinook Therapeutics Inc / ATP Life Science Ventures, L.P. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Chinook Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 16961L 106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| January 13, 2022 |
KDNY / Chinook Therapeutics Inc / Versant Venture Capital VII, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)* Chinook Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 16961L 106 (CUSIP Number) Versant Ve |
|
| November 30, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 24, 2021 Chinook Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commi |
|
| November 30, 2021 |
Exhibit 99.1 Chinook Therapeutics Announces Formation of SanReno Therapeutics, a Joint Venture to Develop Kidney Disease Therapies in China ? 50/50 joint venture with investor syndicate led by Frazier Healthcare Partners and Pivotal bioVenture Partners China ? Expands global reach and execution for Chinook?s atrasentan and BION-1301 programs in IgA nephropathy (IgAN) SEATTLE November 30, 2021 ? Ch |
|
| November 10, 2021 |
424B5 1 d226781d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-255099 PROSPECTUS SUPPLEMENT (To Prospectus dated April 14, 2021) 7,828,572 Shares of Common Stock Pre-funded Warrants to Purchase 3,571,428 Shares of Common Stock CHINOOK THERAPEUTICS, INC. We are offering 7,828,572 shares of our common stock and, in lieu of common stock to certain investors th |
|
| November 10, 2021 |
EXHIBIT 4.1 CHINOOK THERAPEUTICS, INC. FORM OF WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. [ ] Original Issue Date: [ ], 2021 Chinook Therapeutics, Inc., a Delaware corporation (the ?Company?), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns (the ?H |
|
| November 10, 2021 |
Chinook Therapeutics Announces Pricing of an Upsized $160 Million Public Offering EX-99.1 5 d255799dex991.htm EX-99.1 EXHIBIT 99.1 Chinook Therapeutics Announces Pricing of an Upsized $160 Million Public Offering Seattle, WA, November 9, 2021 – Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced the pricing of its upsized underwritten public offering of 7,828,572 shares of its common stock at a price to the public of $14.00 per share. In addition, and in lieu of common st |
|
| November 10, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 CHINOOK THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37345 94-3348934 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 10, 2021 |
Exhibit 1.1 CHINOOK THERAPEUTICS, INC. (a Delaware corporation) 7,828,572 Shares of Common Stock and Pre-Funded Warrants to Purchase 3,571,428 Shares of Common Stock UNDERWRITING AGREEMENT November 9, 2021 SVB Leerink LLC Evercore Group L.L.C. as Representatives of the several Underwriters c/o SVB Leerink LLC 1301 Avenue of the Americas 12th Floor New York, NY 10019 c/o Evercore Group L.L.C. 55 Ea |
|
| November 9, 2021 |
Issuer Free Writing Prospectus Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Dated November 9, 2021 Relating to Preliminary Prospectus Dated November 8, 2021 Registration Statement No. |
|
| November 8, 2021 |
SUBJECT TO COMPLETION, DATED NOVEMBER 8, 2021 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-255099 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell |
|
| November 8, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 Chinook Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commis |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37345 CHINOO |
|
| November 8, 2021 |
Chinook Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results Exhibit 99.1 Chinook Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results SEATTLE November 8, 2021 ? Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the third quarter ende |
|
| September 7, 2021 |
KDNY / Chinook Therapeutics Inc / Versant Venture Capital VII, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* Chinook Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 16961L 106 (CUSIP Number) Versant Ve |
|
| August 12, 2021 |
Chinook Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results Exhibit 99.1 Chinook Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results SEATTLE August 12, 2021 ? Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the second quarter end |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37345 CHINOOK THE |
|
| August 12, 2021 |
Sublease between the Registrant and Wireless Advocates LLC dated May 24, 2021. Exhibit 10.24 SUBLEASE 1. PARTIES. This Sublease (this ?Sublease?), dated May 24, 2021, is made by and between Wireless Advocates LLC, a Washington limited liability company (?Sublandlord?), and Chinook Therapeutics, Inc., a Delaware corporation (?Subtenant?). 2. MASTER LEASE. 400 Fairview Avenue LLC, a Delaware limited liability company, as successor-in-interest to 400 Fairview LLC, a Delaware li |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 Chinook Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commiss |
|
| June 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2021 Chinook Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commissio |
|
| June 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2021 Chinook Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commission |
|
| May 12, 2021 |
Chinook Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results Exhibit 99.1 Chinook Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results SEATTLE May 12, 2021 ? Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the first quarter ended Ma |
|
| May 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2021 Chinook Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commission |
|
| May 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37345 CHINOOK TH |
|
| April 23, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only ( |
|
| April 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 12, 2021 |
[Signature Page to Acceleration Request Letter] Chinook Therapeutics, Inc. 1600 Fairview Avenue East, Suite 100 Seattle, WA 98102 April 12, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Dillon Hagius Re: Chinook Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-255099) Filed April 7, 2021 Requested Date: April 14, 2021 Requeste |
|
| April 7, 2021 |
Subsidiaries of the Registrant Exhibit 21.1 The following table presents the name of significant subsidiaries of Chinook Therapeutics, Inc. and the location of jurisdiction or organization for such subsidiaries. Name: Jurisdiction/Organization Chinook Therapeutics U.S, Inc. Delaware Chinook Therapeutics Canada, Inc. British Columbia, CA Aduro Biotech Holdings, Europe B.V. Netherlands Aduro Biotech Europe B.V. Netherlands Aduro |
|
| April 7, 2021 |
Exhibit 1.2 Execution CHINOOK THERAPEUTICS, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT April 7, 2021 SVB LEERINK LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 CANTOR FITZGERALD & CO. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Chinook Therapeutics, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreemen |
|
| April 7, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2021 Chinook Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commissio |
|
| April 7, 2021 |
Exhibit 4.3 FORM OF DEBT SECURITY [Face of Security] CHINOOK THERAPEUTICS, INC. [If applicable, insert?FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS ?PRINCIPAL AMOUNT?), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT, THE YIELD TO |
|
| April 7, 2021 |
EX-99.1 2 kdny-ex99159.htm EX-99.1 Exhibit 99.1 Chinook Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results SEATTLE April 7, 2021 – Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and report |
|
| April 7, 2021 |
As filed with the Securities and Exchange Commission on April 7, 2021 Registration No. |
|
| April 7, 2021 |
EX-4.4 4 d165801dex44.htm EX-4.4 Exhibit 4.4 CHINOOK THERAPEUTICS, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1 – DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION 4 ARTICLE 2 – THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS |
|
| April 7, 2021 |
Form of Inducement Stock Option Agreement EX-10.23 3 kdny-ex1023981.htm EX-10.23 Exhibit 10.23 Chinook Therapeutics, Inc. Inducement Stock Option Grant Notice As a material inducement to the employment of Optionholder, Chinook Therapeutics, Inc. (the “Company”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is granted separate and apart from, and outside |
|
| April 7, 2021 |
EX-4.2 2 kdny-ex42265.htm EX-4.2 Exhibit 4.2 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2020, Chinook Therapeutics, Inc. (“we,” “us” or “our”) had common stock, $0.0001 par value per share, registered under Section 12 of the Securities Exchange Act of 1934, as amended, and listed on The Nasdaq Global Select Mar |
|
| April 7, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on April 7, 2021 Registration No. |
|
| April 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37345 CHINOOK THERAPE |
|
| March 30, 2021 |
SEC FILE NUMBER 001-37345 CUSIP NUMBER 16961L106 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 16, 2021 |
CUSIP No. 00739L101 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Chinook Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00739L101 (CUSIP Number) Morningside Venture (VI) Investments Ltd. C/O THC Management Services S.A.M. 2nd Floor, Le |
|
| February 16, 2021 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned, being duly authorized thereunder, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule 13D (including amendments thereto) jointly on behalf of each such party. For and o |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Chinook Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 16961L106 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| November 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 19, 2020 CHINOOK THERAPEUTICS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-37345 94-3348934 (State or other jurisdiction of incorporation) (Commi |
|
| November 16, 2020 |
KDNY / Chinook Therapeutics, Inc. / Apple Tree Partners IV, L.P. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Chinook Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 16961L 106 (CUSIP Number) October 5, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| November 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 10, 2020 CHINOOK THERAPEUTICS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-37345 94-3348934 (State or other jurisdiction of incorporation) (Commi |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37345 CHINOO |
|
| November 5, 2020 |
EX-99.1 Table of Contents Exhibit 99.1 INDEX TO CHINOOK CONSOLIDATED FINANCIAL STATEMENTS Periods ended September 30, 2020 and 2019 Page Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations and Comprehensive Loss 2 Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Deficit 3 Condensed Consolidated Statements of Cash Flow |
|
| November 5, 2020 |
Exhibit 10.8 Execution Version CONTINGENT VALUE RIGHTS AGREEMENT BETWEEN ADURO BIOTECH, INC. and Computershare Trust Company, N.A. Dated as of October 2, 2020 ARTICLE 1 DEFINITIONS 3 Section 1.1 Definitions.3 ARTICLE 2 CONTINGENT VALUE RIGHTS 6 Section 2.1 Holders of CVRs; Appointment of Rights Agent.6 Section 2.2 Non-transferable.7 Section 2.3 No Certificate; Registration; Registration of Transfe |
|
| November 5, 2020 |
Sublease between the Registrant and Perfect Day, Inc., dated August 25, 2020 Exhibit 10.9 SUBLEASE THIS SUBLEASE (the “Sublease”) is made as of August 25, 2020 (the “Effective Date”), by and between ADURO BIOTECH, INC., a Delaware corporation (“Sublandlord”), and PERFECT DAY, INC., a Delaware corporation (“Subtenant”). ARTICLE 1 - GENERAL 1.1Master Lease. Seventh Street Properties VII, LLC, a California limited liability company (“Master Landlord”), and Sublandlord, as Ten |
|
| November 5, 2020 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION EX-99.2 3 d89627dex992.htm EX-99.2 Exhibit 99.2 INDEX TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS Page Unaudited Pro Forma Condensed Combined Financial Information 1 Unaudited Pro Forma Condensed Combined Balance Sheet as of September 30, 2020 2 Unaudited Pro Forma Condensed Combined Statement of Operations for Nine Months Ended September 30, 2020 4 Unaudited Pro Forma Condensed |
|
| November 5, 2020 |
Financial Statements and Exhibits - 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 5, 2020 CHINOOK THERAPEUTICS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-37345 94-3348934 (State or other jurisdiction of inc |
|
| October 15, 2020 |
EX-99.1 Exhibit 1 Joint Filing Agreement The undersigned hereby agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that each is responsible for the |
|
| October 15, 2020 |
KDNY / Chinook Therapeutics, Inc. / Versant Venture Capital VII, L.P. - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* Chinook Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 16961L 106 (CUSIP Number) Vers |
|
| October 7, 2020 |
Form of Employment Agreement (US). EX-10.6 Exhibit 10.6 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of [], 2020 (the “Effective Date”) by Chinook Therapeutics, Inc., [or U.S.] a Delaware corporation (the “Company”), and [] (“Executive”) [and amends and restates the employment entered into between the Company and Executive [] (the “Prior Agreement”)]. WHEREAS, the Company |
|
| October 7, 2020 |
Form of Separation Agreement (Standard). EX-10.2 Exhibit 10.2 CONFIDENTIAL SEPARATION AGREEMENT This Confidential Separation Agreement and General Release (the “Agreement”) is made and entered into by and between Aduro Biotech, Inc. (“Aduro”) and (“Employee”) (Aduro and the Employee are referred to collectively as “Parties”). 1. Employment. Employee’s employment with Aduro is ended as of October [5], 2020 (“Separation Date”). 2. Severanc |
|
| October 7, 2020 |
EX-10.4 Exhibit 10.4 CHINOOK THERAPEUTICS, INC. CONSULTING AGREEMENT This CONSULTING AGREEMENT (this “Agreement”) is made effective as of , 2020 (the “Effective Date”), by and between Chinook Therapeutics, Inc., a Delaware corporation (the “Company”) and , (“Consultant”). The Company and Consultant may be referred to herein individually as “Party” or collectively as “Parties.” 1. Work and Payment. |
|
| October 7, 2020 |
Letter from Deloitte & Touche LLP, dated October 7, 2020. EX-16.1 8 d37249dex161.htm EX-16.1 Exhibit 16.1 October 7, 2020 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 Dear Sirs/Madams: We have read Item 4.01 of Chinook Therapeutics, Inc.’s Form 8-K dated October 7, 2020, and have the following comments: 1. We are in agreement with the statements made in part (a) Dismissal of Independent Registered Public Accounting Fi |
|
| October 7, 2020 |
EX-99.1 Exhibit 99.1 Chinook Therapeutics Closes Merger with Aduro Biotech and Completes $115 Million Private Placement Financing Combined Company Will Have Over $275 Million in Operating Capital and Trade on Nasdaq under the Ticker Symbol “KDNY” VANCOUVER, BC and SEATTLE October 5, 2020 – Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biotechnology company focused on the discovery, d |
|
| October 7, 2020 |
Form of Indemnification Agreement. EX-10.5 Exhibit 10.5 INDEMNITY AGREEMENT This Indemnity Agreement, dated as of , 2020 is made by and between Chinook Therapeutics, Inc., a Delaware corporation (the “Company”), and , a director, officer or key employee of the Company or one of the Company’s subsidiaries or other service provider who satisfies the definition of Indemnifiable Person set forth below (“Indemnitee”). RECITALS A. The Co |
|
| October 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 5, 2020 CHINOOK THERAPEUTICS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-35890 94-3348934 (State or other jurisdiction of incorporation) (Commiss |
|
| October 7, 2020 |
Form of Employment Agreement (Canada). EX-10.7 Exhibit 10.7 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of [], 2020 (the “Effective Date”) by Chinook Therapeutics Canada, Inc., a Canadian corporation (the “Company”), and [] (“Executive”) [and amends and restates the employment entered into between the Company and Executive [] (the “Prior Agreement”)]. WHEREAS, the Company des |
|
| October 7, 2020 |
Form of Separation Agreement (Stephen T. Isaacs). EX-10.3 Exhibit 10.3 SEPARATION AGREEMENT AND GENERAL RELEASE OF ALL CLAIMS This Separation Agreement and General Release, dated as of October 5, 2020 (the “Agreement”), is made pursuant to that certain Amended and Restated Executive Employment Agreement made as of July 2, 2020 ( the “Employment Agreement”) entered into by and between Stephen T. Isaacs (“Employee”) on the one hand, and Aduro Biote |
|
| October 6, 2020 |
Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant EX-4.6 Exhibit 4.6 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ADURO BIOTECH, INC. Aduro Biotech, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Company”), hereby certifies as follows: A. The name of this company is Aduro Biotech, Inc., and the original certificate of incorporatio |
|
| October 6, 2020 |
Chinook 2019 Equity Incentive Plan and forms of award agreements thereunder EX-99.1 Exhibit 99.1 CHINOOK THERAPEUTICS U.S., INC. 2019 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: February 6, 2019 APPROVED BY THE STOCKHOLDERS: February 6, 2019 TERMINATION DATE: February 5, 2029 1. General. (a) Eligible Stock Award Recipients. Employees, Directors and Consultants are eligible to receive Stock Awards. (b) Available Stock Awards. The Plan provides for the grant of |
|
| October 6, 2020 |
S-8 As filed with the Securities and Exchange Commission on October 6, 2020 Registration No. |
|
| October 1, 2020 |
EX-99.1 3 d153950dex991.htm EX-99.1 Exhibit 99.1 Aduro Biotech Stockholders Approve Merger Agreement with Chinook Therapeutics One-for-Five Reverse Stock Split to be Effective October 2, 2020 BERKELEY, CA, October 1, 2020 – Aduro Biotech, Inc. (NASDAQ: ADURO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proli |
|
| October 1, 2020 |
Amendment to Amended and Restated Certificate of Incorporation EX-3.1 2 d153950dex31.htm EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ADURO BIOTECH, INC. Aduro Biotech, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Company”), hereby certifies as follows: A. The name of this company is Aduro Biotech, Inc., and the original c |
|
| October 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2020 Aduro Biotech, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commission Fil |
|
| September 24, 2020 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 23, 2020 ADURO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-37345 94-3348934 (State or other jurisdiction of incorporation) (Commiss |
|
| September 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 23, 2020 ADURO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-37345 94-3348934 (State or other jurisdiction of incorporation) (Commission |
|
| September 21, 2020 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 21, 2020 ADURO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-37345 94-3348934 (State or other jurisdiction of incorporation) (Commiss |
|
| September 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 21, 2020 ADURO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-37345 94-3348934 (State or other jurisdiction of incorporation) (Commission |
|
| August 31, 2020 |
Entry into a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 25, 2020 ADURO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-37345 94-3348934 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 26, 2020 |
PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-239989 PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT To the Stockholders of Aduro Biotech, Inc. and Chinook Therapeutics U.S., Inc., Aduro Biotech, Inc., a Delaware corporation, or Aduro, and Chinook Therapeutics U.S., Inc., a Delaware corporation, or Chinook, entered into an Agreement and Plan of Merger and Reorganization |
|
| August 24, 2020 |
Consent of Jerel Davis to be named as director EX-99.3 8 d949502dex993.htm EX-99.3 Exhibit 99.3 Chinook Therapeutics U.S., Inc. 1600 Fairview Avenue East, Suite 100 Seattle, WA 98102 Consent to Reference in Proxy Statement/Prospectus Aduro Biotech, Inc. (“Aduro”) is filing a Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith |
|
| August 24, 2020 |
Consent of Eric Dobmeier to be named as director EX-99.2 7 d949502dex992.htm EX-99.2 Exhibit 99.2 Chinook Therapeutics U.S., Inc. 1600 Fairview Avenue East, Suite 100 Seattle, WA 98102 Consent to Reference in Proxy Statement/Prospectus Aduro Biotech, Inc. (“Aduro”) is filing a Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith |
|
| August 24, 2020 |
S-4/A 1 d949502ds4a.htm S-4/A Table of Contents As filed with the Securities and Exchange Commission on August 24, 2020 Registration No. 333-239989 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to Form S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aduro Biotech, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 94-3348 |
|
| August 24, 2020 |
CORRESP 140 Scott Drive Menlo Park, California 94025 Tel: +1.650.328.4600 Fax: +1.650.463.2600 www.lw.com FIRM / AFFILIATE OFFICES August 24, 2020 Beijing Boston Brussels Century City Chicago Dubai Düsseldorf Frankfurt Hamburg Hong Kong Houston London Los Angeles Madrid Milan Moscow Munich New York Orange County Paris Riyadh San Diego San Francisco Seoul Shanghai Silicon Valley Singapore Tokyo Was |
|
| August 24, 2020 |
Consent of Michelle Griffin to be named as director EX-99.5 Exhibit 99.5 Michelle Griffin c/o Chinook Therapeutics U.S., Inc. 1600 Fairview Avenue East, Suite 100 Seattle, WA 98102 Consent to Reference in Proxy Statement/Prospectus Aduro Biotech, Inc. (“Aduro”) is filing a Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I her |
|
| August 24, 2020 |
CORRESP Aduro Biotech, Inc. 740 Heinz Avenue Berkeley, California 94710 August 24, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Re: Aduro Biotech, Inc. Registration Statement on Form S-4 (File No. 333-239989) Request for Acceleration of Effectiveness Requested Date: August 26, 2020 Requested Time: 9:0 |
|
| August 24, 2020 |
Form of Preliminary Proxy Card of Aduro Biotech, Inc. EX-99.1 6 d949502dex991.htm EX-99.1 Exhibit 99.1 740 HEINZ AVENUE BERKELEY, CA 94710 VOTE BY INTERNET Before The Meeting - Go to www.proxyvote.com Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 P.M. Eastern Time the day before the cut-off date or meeting date. Have your proxy card in hand when you access the web site and follow the i |
|
| August 24, 2020 |
Consent of Srinivas Akkaraju to be named as director EX-99.4 9 d949502dex994.htm EX-99.4 Exhibit 99.4 Chinook Therapeutics U.S., Inc. 1600 Fairview Avenue East, Suite 100 Seattle, WA 98102 Consent to Reference in Proxy Statement/Prospectus Aduro Biotech, Inc. (“Aduro”) is filing a Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith |
|
| August 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 17, 2020 ADURO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-37345 94-3348934 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 18, 2020 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 17, 2020 ADURO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-37345 94-3348934 (State or other jurisdiction of incorporation) (Commission |
|
| August 18, 2020 |
425 Filed by Aduro Biotech, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Chinook Therapeutics U.S., Inc. Commission File No. 001-37345 This filing relates to the proposed merger of Chinook Therapeutics U.S., Inc., a Delaware corporation (“Chinook”), with Aspire Merger Sub, Inc. (“Merge |
|
| August 18, 2020 |
EX-10.1 Exhibit 10.1 Execution Version NOTE TERMINATION AGREEMENT This Note Termination Agreement (this “Agreement”) is made and entered into as of August 17, 2020 by and among Chinook Therapeutics U.S., Inc., a Delaware corporation (the “Company”), the parties listed in Exhibit A (each, individually, an “Investor” and collectively, the “Investors”), and Aduro Biotech, Inc., a Delaware corporation |
|
| August 18, 2020 |
EX-2.1 Exhibit 2.1 AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER AND REORGANIZATION THIS AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Amendment”) is made and entered into as of August 17, 2020, by and among ADURO BIOTECH, INC., a Delaware corporation (“Parent”), ASPIRE MERGER SUB, INC., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and |
|
| August 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2020 Aduro Biotech, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commission File |
|
| August 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37345 ADURO BIOTE |
|
| August 3, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2020 Aduro Biotech, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commission File |
|
| August 3, 2020 |
Aduro Biotech Provides Business Update and Reports Second Quarter 2020 Financial Results EX-99.1 2 adro-ex9916.htm EX-99.1 Exhibit 99.1 Contact: Noopur Liffick Investor Relations & Corporate Affairs 510-809-2465 [email protected] [email protected] Aduro Biotech Provides Business Update and Reports Second Quarter 2020 Financial Results BERKELEY, California, August 3, 2020 – Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies ta |
|
| July 22, 2020 |
S-4 Table of Contents As filed with the Securities and Exchange Commission on July 21, 2020 Registration No. |
|
| July 22, 2020 |
Form of Preliminary Proxy Card of Aduro Biotech, Inc. EX-99.1 Exhibit 99.1 740 HEINZ AVENUE BERKELEY, CA 94710 VOTE BY INTERNET Before The Meeting - Go to www.proxyvote.com Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 P.M. Eastern Time the day before the cut-off date or meeting date. Have your proxy card in hand when you access the web site and follow the instructions to obtain your r |
|
| July 22, 2020 |
EX-10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. Exhibit 10.1 LICENSE AGREEMENT between ABBVIE IRELAND UNLIMITED COMPANY and CHINOOK THERAPEUTICS U.S., INC. Dated as of December 16, 2019 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOC |
|
| July 17, 2020 |
Amendment to Amended and Restated Bylaws, dated July 16, 2020 EX-3.1 Exhibit 3.1 AMENDMENT TO THE BYLAWS OF ADURO BIOTECH, INC., a Delaware corporation In accordance with a resolution approved by the Board of Directors of Aduro Biotech, Inc., a Delaware corporation (the “Company”), on July 16, 2020, the bylaws of the Company (the “Bylaws”) are hereby amended as follows: 1. Article XV shall be amended and restated in its entirety to read as follows: “ARTICLE |
|
| July 17, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 16, 2020 ADURO BIOTECH, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-37345 94-3348934 (State or other jurisdiction of incorporation) (Commission F |
|
| July 2, 2020 |
Letter Agreement by and between the Company and Blaine Templeman, dated July 29, 2020 EX-10.3 Exhibit 10.3 June 29, 2020 Blaine Templeman *** *** Re: Option Extension Dear Blaine: This letter is to inform you that in connection with entering into the proposed merger transaction pursuant to the that certain Agreement and Plan of Merger and Reorganization among Aduro Biotech, Inc. (the “Company”), Aspire Merger Sub, Inc., and Chinook Therapeutics U.S., Inc. dated as of June 1, 2020 ( |
|
| July 2, 2020 |
EX-10.1 2 d34680dex101.htm EX-10.1 Exhibit 10.1 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made as of this 2nd day of July, 2020 (the “Effective Date”), by and between Aduro Biotech, Inc., a Delaware corporation (the “Company”), and Stephen T. Isaacs (“Executive”) (collectively, the “Parties”). WHEREAS, the Parties wish to amend and restate t |
|
| July 2, 2020 |
EX-10.2 Exhibit 10.2 AMENDMENT TO THE ADURO BIOTECH, INC. AMENDED AND RESTATED SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION This Amendment (this “Amendment”) to the Aduro Biotech, Inc. Amended and Restated Severance Plan and Summary Plan Description (the “Severance Plan”), is made and adopted by the Board of Directors (the “Board”) of Aduro Biotech, Inc., a Delaware corporation (the “Company”), eff |
|
| July 2, 2020 |
425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2020 Aduro Biotech, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commission F |
|
| July 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2020 Aduro Biotech, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commission File |
|
| June 11, 2020 |
ADRO / Aduro Biotech, Inc. / Vivo Capital IX, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aduro Biotech, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 00739L101 (CUSIP Number) February 21, 2020** (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| June 10, 2020 |
425 Filed by Aduro Biotech, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Chinook Therapeutics U.S., Inc. Commission File No. 001-37345 This filing relates to the proposed merger of Chinook Therapeutics U.S., Inc., a Delaware corporation (“Chinook”), with Aspire Merger Sub, Inc. (“Merge |
|
| June 10, 2020 |
425 Filed by Aduro Biotech, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Chinook Therapeutics U.S., Inc. Commission File No. 001-37345 This filing relates to the proposed merger of Chinook Therapeutics U.S., Inc., a Delaware corporation (“Chinook”), with Aspire Merger Sub, Inc. (“Merge |
|
| June 5, 2020 |
425 Filed by Aduro Biotech, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Chinook Therapeutics U.S., Inc. Commission File No. 001-37345 This filing relates to the proposed merger of Chinook Therapeutics U.S., Inc., a Delaware corporation (“Chinook”), with Aspire Merger Sub, Inc. (“Merge |
|
| June 3, 2020 |
Form 425 Filed by Aduro Biotech, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Chinook Therapeutics U.S., Inc. Commission File No. 001-37345 Chinook Therapeutics – Aduro Biotech and Chinook Therapeutics Definitive Merger Agreement, June 2, 2020 C O R P O R A T E P A R T I C I P A N T S |
|
| June 2, 2020 |
EX-10.3 Exhibit 10.3 FORM OF SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”), dated as of June 1, 2020, is by and between Aduro Biotech, Inc., a Delaware corporation (“Parent”), and the Person set forth on Schedule A (the “Stockholder”). WHEREAS, concurrently with the execution and delivery hereof, Parent, Aspire Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsid |
|
| June 2, 2020 |
EX-10.1 Exhibit 10.1 NOTE PURCHASE AGREEMENT This Note Purchase Agreement (this “Agreement”) is made as of June 1, 2020 by and among Chinook Therapeutics U.S., Inc., a Delaware corporation (the “Company”), and the parties listed on the Schedule of Investors attached to this Agreement as Exhibit A (each, individually, an “Investor” and collectively, the “Investors”). A. WHEREAS, the Company current |
|
| June 2, 2020 |
425 Filed by Aduro Biotech, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Chinook Therapeutics U.S., Inc. Commission File No. 001-37345 This filing relates to the proposed merger of Chinook Therapeutics U.S., Inc., a Delaware corporation (“Chinook”), with Aspire Merger Sub, Inc. (“Merge |
|
| June 2, 2020 |
EX-10.3 Exhibit 10.3 FORM OF SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”), dated as of June 1, 2020, is by and between Aduro Biotech, Inc., a Delaware corporation (“Parent”), and the Person set forth on Schedule A (the “Stockholder”). WHEREAS, concurrently with the execution and delivery hereof, Parent, Aspire Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsid |
|
| June 2, 2020 |
Form of Convertible Promissory Note. EX-10.2 Exhibit 10.2 NEITHER THIS NOTE NOR THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF APPLICABLE STATES. THIS NOTE AND SUCH SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD, INCLUDING WITHOUT LIMITATION PURSUANT TO ANY SWA |
|
| June 2, 2020 |
425 Filed by Aduro Biotech, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Chinook Therapeutics U.S., Inc. Commission File No. 001-37345 This filing relates to the proposed merger of Chinook Therapeutics U.S., Inc., a Delaware corporation (“Chinook”), with Aspire Merger Sub, Inc. (“Merge |
|
| June 2, 2020 |
EX-10.4 Exhibit 10.4 FORM OF SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”), dated as of June 1, 2020, is by and between Chinook Therapeutics U.S., Inc., a Delaware corporation (the “Company”), and the Person set forth on Schedule A (the “Stockholder”). WHEREAS, concurrently with the execution and delivery hereof, Aduro Biotech, Inc., a Delaware corporation (“Parent”), Aspire Merger S |
|
| June 2, 2020 |
EX-10.6 Exhibit 10.6 FINAL FORM EXHIBIT F CONTINGENT VALUE RIGHTS AGREEMENT BETWEEN ADURO BIOTECH, INC. and COMPUTERSHARE TRUST COMPANY, N.A. Dated as of [•] ARTICLE 1 DEFINITIONS 3 Section 1.1 Definitions. 3 ARTICLE 2 CONTINGENT VALUE RIGHTS 7 Section 2.1 Holders of CVRs; Appointment of Rights Agent. 7 Section 2.2 Non-transferable. 7 Section 2.3 No Certificate; Registration; Registration of Trans |
|
| June 2, 2020 |
EX-99.2 Developing Precision Medicines for Kidney Diseases Merger Announcement June 2, 2020 Exhibit 99.2 Note Regarding Forward-Looking Statements Certain of the statements made in this presentation are forward looking for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including those relating to the benefits of the merger, future management and the |
|
| June 2, 2020 |
EX-99.2 Developing Precision Medicines for Kidney Diseases Merger Announcement June 2, 2020 Exhibit 99.2 Note Regarding Forward-Looking Statements Certain of the statements made in this presentation are forward looking for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including those relating to the benefits of the merger, future management and the |
|
| June 2, 2020 |
EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: ADURO BIOTECH, INC., a Delaware corporation; ASPIRE MERGER SUB, INC., a Delaware corporation; and CHINOOK THERAPEUTICS U.S., INC., a Delaware corporation Dated as of June 1, 2020 Table of Contents Page SECTION 1. DESCRIPTION OF TRANSACTION 2 1.1 The Merger 2 1.2 Effects of the Merger 3 1.3 Closing; Effective Time 3 1.4 Certi |
|
| June 2, 2020 |
EX-10.7 Exhibit 10.7 CONSULTING AGREEMENT Aduro Biotech, Inc., with a place of business at 740 Heinz Avenue, Berkeley, CA 94710 (“Aduro”) and IREYA B.V having an address at Staalwijkstraat 16, 2313 XR Leiden, the Netherlands, represented by Andrea van Elsas, (“Consultant”) agree to all terms and conditions of this Consulting Agreement (“Agreement”) dated June 1, 2020, effective as of July 1, 2020 |
|
| June 2, 2020 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2020 Aduro Biotech, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commissi |
|
| June 2, 2020 |
Form of Convertible Promissory Note EX-10.2 Exhibit 10.2 NEITHER THIS NOTE NOR THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF APPLICABLE STATES. THIS NOTE AND SUCH SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD, INCLUDING WITHOUT LIMITATION PURSUANT TO ANY SWA |
|
| June 2, 2020 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2020 Aduro Biotech, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37345 94-3348934 (Commissi |
|
| June 2, 2020 |
EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: ADURO BIOTECH, INC., a Delaware corporation; ASPIRE MERGER SUB, INC., a Delaware corporation; and CHINOOK THERAPEUTICS U.S., INC., a Delaware corporation Dated as of June 1, 2020 Table of Contents Page SECTION 1. DESCRIPTION OF TRANSACTION 2 1.1 The Merger 2 1.2 Effects of the Merger 3 1.3 Closing; Effective Time 3 1.4 Certi |
|
| June 2, 2020 |
EX-10.1 Exhibit 10.1 NOTE PURCHASE AGREEMENT This Note Purchase Agreement (this “Agreement”) is made as of June 1, 2020 by and among Chinook Therapeutics U.S., Inc., a Delaware corporation (the “Company”), and the parties listed on the Schedule of Investors attached to this Agreement as Exhibit A (each, individually, an “Investor” and collectively, the “Investors”). A. WHEREAS, the Company current |
|
| June 2, 2020 |
EX-99.1 Exhibit 99.1 Aduro Biotech and Chinook Therapeutics Announce Definitive Merger Agreement – Combined Company Will Operate as Chinook Therapeutics and Advance Pipeline of Clinical-Stage Programs in Kidney Diseases, Led by Atrasentan and BION-1301 in IgA Nephropathy – Combined Company Will be Well-Funded With Cash Position of ~$200 Million Expected at Closing, Including $25 Million in Additio |
|
| June 2, 2020 |
EX-10.5 Exhibit 10.5 FORM OF LOCK-UP AGREEMENT June 1, 2020 [ ] Ladies and Gentlemen: The undersigned signatory (the “Stockholder”) of this lock-up agreement (this “Agreement”) understands that: (i) Aduro Biotech, Inc., a Delaware corporation (“Parent”) proposes to enter into an Agreement and Plan of Merger and Reorganization (as the same may be amended from time to time, the “Merger Agreement”) w |
|
| June 2, 2020 |
EX-10.4 Exhibit 10.4 FORM OF SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”), dated as of June 1, 2020, is by and between Chinook Therapeutics U.S., Inc., a Delaware corporation (the “Company”), and the Person set forth on Schedule A (the “Stockholder”). WHEREAS, concurrently with the execution and delivery hereof, Aduro Biotech, Inc., a Delaware corporation (“Parent”), Aspire Merger S |
|
| June 2, 2020 |
EX-10.7 Exhibit 10.7 CONSULTING AGREEMENT Aduro Biotech, Inc., with a place of business at 740 Heinz Avenue, Berkeley, CA 94710 (“Aduro”) and IREYA B.V having an address at Staalwijkstraat 16, 2313 XR Leiden, the Netherlands, represented by Andrea van Elsas, (“Consultant”) agree to all terms and conditions of this Consulting Agreement (“Agreement”) dated June 1, 2020, effective as of July 1, 2020 |
|
| June 2, 2020 |
425 Filed by Aduro Biotech, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Chinook Therapeutics U.S., Inc. Commission File No. 001-37345 This filing relates to the proposed merger of Chinook Therapeutics U.S., Inc., a Delaware corporation (“Chinook”), with Aspire Merger Sub, Inc. (“Merge |
|
| June 2, 2020 |
EX-99.1 Exhibit 99.1 Aduro Biotech and Chinook Therapeutics Announce Definitive Merger Agreement – Combined Company Will Operate as Chinook Therapeutics and Advance Pipeline of Clinical-Stage Programs in Kidney Diseases, Led by Atrasentan and BION-1301 in IgA Nephropathy – Combined Company Will be Well-Funded With Cash Position of ~$200 Million Expected at Closing, Including $25 Million in Additio |
